Weekly Recap: Phase2 ARCT-2601 addition and FDA pediatric ammonia endpoint

Arcturus Therapeutics Holdings, Inc. (NASDAQ:ARCT) will add ARCT-2601 to its Phase 2 ARCT-810 trial after an FDA meeting, planning year—end dosing in OTCD patients to assess safety, PK and biomarkers while pursuing longer metabolic studies and new liver-focused PKU/gout programs.Previous Week Recap…